Overview of Pehacain

Property	Description
Active ingredients	Lidocaine Hydrochloride and Adrenaline (Epinephrine)
Form	Sterile solution for injection
Pharmacological class	Local Anesthetic and Adrenergic Agonist Combination
Common use	Production of local or regional anesthesia/analgesia
Origin	Synthetic (Lidocaine) and Sympathomimetic (Adrenaline)

Defining Pehacain: A Combination Local Anesthetic

Pehacain is a specialized parenteral drug product classified as a Local Anesthetic and Adrenergic Agonist Combination. This formulation, delivered as a sterile solution for injection, is designed for the production of local or regional anesthesia/analgesia. This class is widely recognized for its reliable action in procedures requiring temporary and focused loss of sensation. The primary function of Lidocaine, the key anesthetic component, is to effectively block pain signals at the nerve level.

Composition: Lidocaine Hydrochloride and Adrenaline

The medicine contains two distinct active ingredients: Lidocaine Hydrochloride and Adrenaline (Epinephrine). Lidocaine Hydrochloride is the main anesthetic agent, identified as an amide-type synthetic local anesthetic. Adrenaline (Epinephrine) is a sympathomimetic agent that functions as a potent vasoconstrictor. This particular combination is a standard formulation, as the strategic addition of a vasoconstrictor like Epinephrine is a well-established practice to extend the anesthetic effect. This verifies that the product is a deliberately formulated combination product designed for optimized performance and duration in localized settings.

Primary Function: Neuronal Blockade and Vasoconstriction

The core physiological action of Pehacain is achieved through a synergistic mechanism that is broadly supported by pharmacological principles. Lidocaine Hydrochloride performs the essential neuronal signal blockade, which halts nerve transmission and ensures the production of numbness. Concurrently, the Adrenaline component causes immediate localized narrowing of the blood vessels (vasoconstriction). This action minimizes the absorption of the anesthetic into the general circulation, a mechanism clinically recognized for reducing systemic exposure while simultaneously ensuring the drug’s concentration remains high in the target tissue. Consequently, the primary benefit is the significant prolongation of local effects, which reliably guarantees a sustained absence of feeling for the necessary duration of intervention.

Regulatory References

FDA Drug Labeling (Lidocaine and Epinephrine)

What side effects are possible with Pehacain?

Possible Side Effects and Safety Information

Pehacain (a combination product containing a local anesthetic, likely lidocaine, and a vasoconstrictor, like epinephrine) carries risks primarily related to high systemic concentrations of the anesthetic agent or the effects of the vasoconstrictor.

Adverse Reactions

The most common adverse reactions involve the Central Nervous System (CNS) and the Cardiovascular System and are often dose-related. Early CNS signs may include lightheadedness, nervousness, apprehension, confusion, dizziness, or drowsiness, which can progress to twitching, tremors, convulsions, and ultimately, respiratory depression and arrest. Cardiovascular reactions include bradycardia, hypotension, decreased cardiac output, ventricular arrhythmias (such as ventricular fibrillation), and cardiac arrest.

System-Organ Class	Clinically Significant Adverse Reactions
Cardiovascular	Hypotension, Bradycardia, Cardiac Arrest, Cardiovascular Collapse.
Nervous System	Convulsions, Respiratory Arrest, Persistent Paresthesia (rarely lasting over a year).
Hematologic	Methemoglobinemia (a rare but serious blood disorder).
Immune System	Allergic reactions, including anaphylactoid reactions, may occur due to sensitivity to the anesthetic agent or preservatives (e.g., sodium metabisulfite or methylparaben).

Population-Specific and Use Restrictions

Vulnerable Populations: Caution is advised when administering the drug to pediatric patients (especially those younger than 6 months due to increased toxicity risk), elderly patients, and those with severe shock, heart block, severe liver disease, or certain pre-existing cardiac conditions.
Restrictions: Preparations containing epinephrine must be used with caution in patients receiving certain medications (e.g., non-selective beta-blockers, tricyclic antidepressants, MAO inhibitors) due to the risk of severe hypertension and cardiac arrhythmias.
Monitoring: Continuous monitoring of the patient's cardiovascular and respiratory vital signs and state of consciousness is mandated during and immediately following administration to detect signs of systemic toxicity.

Overdose and Emergency Response

The official regulatory documentation for Pehacain overdose describes acute systemic toxicity that primarily affects the Central Nervous System (CNS) and the Cardiovascular System. Toxicity may result from a rapid increase in plasma concentrations due to administration error or accidental intravascular injection.

Documented Manifestations and Outcomes

Signs of systemic toxicity typically begin with initial CNS manifestations such as dizziness, lightheadedness, tinnitus, and numbness around the mouth (circumoral paraesthesia). Progression can rapidly lead to severe outcomes, including generalized convulsions, unconsciousness, respiratory arrest, and cardiovascular collapse involving ventricular arrhythmias and cardiac arrest. A serious hematologic complication, methemoglobinemia, characterized by cyanotic skin discoloration, is also a documented risk.

When to Seek Immediate Help

Regulatory labeling mandates that individuals seek immediate medical attention upon the recognition of any signs of systemic toxicity. Immediate treatment is required to avert life-threatening cardiovascular and CNS effects. Management is described as symptomatic and supportive, as no specific antidote is known for the combination product. Close monitoring of consciousness, and cardiovascular and respiratory vital signs is required. Increased risk of developing toxic plasma concentrations is documented for elderly or acutely ill patients and those with severe hepatic disease.

Therapeutic Uses of Pehacain

What Pehacain Treats: Main Uses and Benefits

Pehacain is relevant for managing symptoms related to physical discomfort and acute sensations that may arise from minor clinical interventions. It is commonly used to help with symptomatic relief, which may assist with maintaining functional stability during procedures. This combination drug is relevant for easing symptoms related to physical discomfort during surgical, dental, oral surgery, diagnostic, therapeutic, and obstetrical procedures.

Applied across domains where additional symptomatic support is needed, this medication is commonly used across conditions presenting with acute episodes requiring short-term intervention. The medication also supports the management of localized bleeding, which contributes to improved comfort during periods of heightened symptoms. It is applied in clinical settings that involve acute or unstable symptom patterns, which may provide support that helps ease the overall symptom burden.

“Pehacain may assist with maintaining functional stability and support the patient during difficult episodes by easing distress related to temporary functional strain.”

Quick Fact: Relief for Acute Procedural Pain

Pehacain is commonly used in situations requiring short-term symptomatic support, such as before procedures for treating lacerations, dental extractions, or minor skin biopsies.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Pehacain — Official Regulatory Information

The eligibility for Pehacain (Lidocaine/Epinephrine combination) is defined by official regulatory documentation, focusing on hypersensitivity, patient status, and specific medical conditions.

Eligibility Scope

Category	Eligibility Rule	Status / Classification
Populations Contraindicated	Known hypersensitivity to amide-type local anesthetics or formulation components (e.g., sodium metabisulfite).	Absolute Contraindication
Anatomical Restriction	Anesthesia in areas supplied by end arteries (e.g., fingers, nose, toes) due to the vasoconstrictor component.	Contraindicated

Category	Eligibility Rule	Status / Classification
Age-Related Rule	Children younger than two years of age.	Use Not Established (Insufficient data)
Age-Related Rule	Infants under six months of age.	Use with Extreme Caution
Conditional Use	Elderly, acutely ill, or debilitated patients.	Conditional Use (Requires reduced dose)
Conditional Use	Patients with severe shock, heart block, or hepatic impairment.	Use with Caution / Increased Monitoring
Physiological Status	Pregnant women (FDA Category B); Lactating women.	Conditional Use; Acceptable (for lactation)

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Absolute Contraindication; Conditional Use / Caution; Use Not Established.

Eligibility-context constraints (as defined in official documents): Constraints are based on specific anatomical sites, component sensitivity, cardiac or vascular comorbidities, and reduced metabolic capacity (hepatic impairment).

Official eligibility statements: Regulatory documents explicitly state that use is contraindicated in patients with a history of amide-type anesthetic allergy or when used in body areas with a compromised blood supply. For eligible populations, use is often conditional, requiring careful patient status assessment for the very young, the elderly, or those with underlying severe cardiac or liver disease, as explicitly stated in the FDA and EMA labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify interactions with Pehacain (Lidocaine and Adrenaline) primarily into two types: those affecting the cardiovascular system and those altering drug exposure.

Contraindicated and Pharmacodynamic Interactions

Co-administration with certain medicinal products is documented to cause significant pharmacodynamic effects, often leading to restricted use.

Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may potentiate the pressor effects of the Adrenaline component, carrying the risk of severe, prolonged hypertension.
Co-use with Ergot-type Oxytocic drugs is documented to cause severe persistent hypertension, a formally restricted combination.
Nonselective Beta-blockers may cause severe hypertension and bradycardia due to the unopposed vasoconstriction from Adrenaline.
The toxic effects are additive when co-administered with other local anesthetics or Class I antiarrhythmic drugs like Mexiletine, increasing the risk of systemic toxicity.
Potent Inhalation Anesthetics, such as Halothane, can sensitize the myocardium, increasing the risk of dose-related cardiac arrhythmias when combined with Adrenaline.

Pharmacokinetic Interactions (Exposure Risk)

Interactions documented to affect the clearance of the anesthetic component result in altered systemic exposure.

CYP1A2 Inhibitors, such as Cimetidine, can reduce the metabolic clearance of Lidocaine, resulting in documented increased plasma concentrations of the anesthetic component.
Medicines that reduce hepatic blood flow, such as Propranolol, can impair the rate at which Lidocaine is metabolized and cleared, leading to potentially higher systemic exposure.

Mechanism of Action

Pehacain utilizes the complementary actions of two active agents to create a localized and sustained interruption of nerve signaling, engaging mechanisms that interrupt nerve impulse transmission and modulate local blood flow dynamics.

Molecular Blockade of Nerve Impulse Conduction

This domain covers the primary role of Lidocaine Hydrochloride, which acts by targeting and physically blocking Voltage-Gated Sodium Channels ( Na V channels) on peripheral sensory neurons. This molecular interference prevents the necessary influx of sodium ions required for the nerve to generate an electrical impulse, functionally halting the transmission of signals. The resulting physiological effect is the temporary and reversible cessation of nerve conduction in the treated area.

Sympathomimetic Regulation of Clearance

This domain focuses on the mechanism of Adrenaline (Epinephrine), which is an active agonist of local alpha1-adrenergic receptors on vascular smooth muscle. Activation of these receptors causes localized vasoconstriction (narrowing of blood vessels) at the site of administration. This regulation of local blood flow mechanically slows the rate at which Lidocaine is carried away, maintaining the anesthetic concentration in the target tissue to prolong the functional duration of the nerve blockade.

Mechanism Constraint and Differential Susceptibility

The mechanism is constrained by the physical properties of the nerve fibers themselves, leading to differential susceptibility. This means the molecular blockade preferentially affects small-diameter, unmyelinated nerve fibers (such as those responsible for nociceptive signaling) before affecting larger motor fibers. This physiological constraint dictates the specific, sequential way in which afferent nerve signal processing and motor function are temporarily modulated.

Dosage and Administration Information

Pehacain is a sterile solution intended for acute procedural administration to achieve local or regional anesthesia. Its usage is defined by clinical guidelines, limiting it to single, short-term applications. It is strictly not intended for continuous or long-term maintenance therapy.

Administration Routes and Dosing Limits

The medicine is administered through parenteral injection via several techniques, including infiltration into tissue, peripheral nerve block, and central neural techniques like lumbar epidural or caudal block. The professional administering the drug must be experienced in these regional anesthesia techniques. The fundamental dosing principle is to use the lowest effective dose required for the procedure. The maximum single dose of the active anesthetic component, Lidocaine, should not exceed 500 mg when combined with Epinephrine for most adult regional blocks. For specific, highly sensitive blocks, such as a paracervical block, the total limit is lowered to 200 mg over a 90-minute period.

Preparation and Injection Technique

Before use, the solution must be visually inspected for discoloration or particulate matter; any affected solution must not be used. The drug must be delivered slowly or in incremental (fractional) doses. A critical procedural step is to aspirate prior to the initial and any subsequent injection to prevent accidental entry into a blood vessel or the subarachnoid space. Furthermore, formulations containing antimicrobial preservatives are restricted and must not be used for epidural or caudal anesthesia.

Population-Specific Adjustments

Dose adjustments are indicated for vulnerable populations. Dosing for older adults (geriatric) and patients with hepatic impairment requires reduction commensurate with the individual’s physical condition. For pediatric patients (aged 1 to 11 years), the maximum dose of the Lidocaine component must be calculated based on body weight, typically limited to 7 mg/kg.

Recent Clinical Evidence

Research evidence / Overview of studies for Pehacain

Research for the combination of Lidocaine and Adrenaline (Epinephrine) includes clinical studies and analyses that have examined its use in regional and local anesthesia. The evidence base primarily consists of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews that evaluate the effects of combining the two active components. Research does not determine whether an individual will respond similarly; findings describe group patterns observed in the studies.

Evidence for Local or Regional Anesthesia

Research explored outcomes such as the time needed for numbness to start and the overall duration until feeling completely returned. Studies found the combination compared to Lidocaine alone was associated with a longer measured duration of the loss of sensation. This finding is relevant in trials assessing short-term symptom patterns. However, research highlights that evidence quality varies across studies, and concerns regarding methodological bias have been noted in some systematic reviews.

Evidence for Vasoconstriction and Managing Local Bleeding

This area details research that assessed the Adrenaline component’s role in affecting local blood flow and assisting with hemostasis (managing local bleeding). Studies report that when the combination was observed in some trials, it was associated with lower measurements of localized bleeding compared to measurements taken with plain Lidocaine. The data for certain patient subgroups remain limited, and the research includes discussions on the balance of observed changes in anatomical areas with restricted circulation.

Summary of Research Gaps and Uncertainty

Clinical studies evaluating this medicine generally focus on the immediate procedural effects. The follow-up durations were limited, and consequently, there is limited information for long-term outcomes that go beyond the short-term changes measured during the study period. A key limitation is that sample sizes were modest in some systematic reviews, and evidence quality varies across studies, particularly when examining specific surgical sites. The results apply only to the specific populations studied.

Key Studies & References Lidocaine Hydrochloride and Epinephrine Injection, Solution - Full Prescribing Information

Frequently Asked Questions (FAQ)

Common questions about Pehacain (FAQ)

Q: Is Pehacain the same kind of drug as [common similar drug name]?

Pehacain is officially classified as a Local Anesthetic and Adrenergic Agonist Combination. This means it pairs an amide-type numbing agent (Lidocaine) with a blood vessel constrictor (Epinephrine). This specific formulation is a standard combination used in medical procedures to ensure local numbing and prolonged effect.

Q: Is Pehacain safe for use in older adults?

Official guidelines indicate that use in older (geriatric), acutely ill, or debilitated patients is conditional. Regulatory documents note that dose adjustments are necessary in these populations to align with their individual physical status. This precaution is in place to manage the risk of potential systemic effects.

Q: Can Pehacain affect my ability to drive or operate machinery?

The official product information advises caution when driving or operating machinery after the procedure. This is due to the risk of common side effects involving the central nervous system, which can include temporary drowsiness, dizziness, or slowed reflexes. The need for caution should be discussed with the administering professional.

Q: Does Pehacain cause any problems with sleep?

The product's label notes that it is associated with Central Nervous System (CNS) effects that include drowsiness and confusion. While specific sleep problems like insomnia are not explicitly listed, the overall effect of CNS depression is documented. Any unexpected reaction is a factor to be managed by the administering professional.

Q: What does 'contraindication' mean in relation to Pehacain?

A contraindication is a medically necessary reason to prohibit the use of a medicine. Regulatory sources define it as a condition or factor that could potentially cause harm to the patient if the drug were administered. For Pehacain, contraindications include known allergies to amide-type anesthetics and use in certain body areas.

Q: Are the reported side effects of Pehacain common or rare?

Official safety information indicates that the most frequent adverse reactions are often dose-related and involve the central nervous system, such as dizziness or confusion. More severe outcomes, such as methemoglobinemia, are described in official documents as rare but serious and are part of the required continuous monitoring.

Q: What are the warning signs of an allergic reaction to Pehacain?

Official regulatory documents describe signs of an immediate allergic reaction that include swelling of the face, tongue, or throat, known as angioedema. Other documented signs are wheezing, dizziness, difficulty breathing, and a widespread rash. Continuous patient monitoring is required during and immediately following administration.

Q: Does the research suggest Pehacain is better than placebo?

Clinical studies generally evaluate the product by comparing the combination against the anesthetic component, Lidocaine, when used alone. This comparison is used to assess the added benefits of Epinephrine, such as its role in prolonging the numbing effect and assisting with local blood flow regulation.

Q: Is Pehacain effective for treating all the conditions it is approved for?

Studies and official information indicate that the product is indicated for local anesthesia, but the research base has limitations. Regulatory summaries state that the quality of evidence varies across studies, and there is limited information available concerning outcomes that extend beyond the short term.

Q: How long does it take for Pehacain to start working?

The time it takes for the numbing effect to begin, known as the onset of action, depends on several procedural factors. Official information indicates this time is based on the route of administration, concentration used, and the specific site of injection. Onset may range from a few minutes for simple infiltration to longer periods, such as 10 to 15 minutes, for certain deeper nerve blocks.

Q: Is Pehacain the generic or brand name of the drug?

Pehacain is described in official documentation as a brand name for the combination product. The formulation contains the two active ingredients, Lidocaine Hydrochloride (the anesthetic agent) and Epinephrine (the vasoconstrictor).

Q: Do I need any special tests before starting Pehacain?

Prior to a full dose, especially when the drug is administered via the epidural route, official documents recommend the use of a test dose. Furthermore, continuous monitoring of the patient's heart function and state of consciousness is mandated during and immediately following the procedure.

Q: Why are people talking about Pehacain on health forums?

The product's active agents are among the most commonly used for generating local and regional anesthesia across medical procedures. The widespread use in procedures like dental work and minor surgery is the factual basis for its high visibility and discussion.

Q: Can Pehacain be used alongside supplements or vitamins?

Official regulatory labels explicitly list known interactions with other prescription medicines. However, information regarding interactions with all possible herbal or vitamin supplements is often not available. Due to the potential for unknown interactions, this information should be communicated to the administering professional.

Q: Is Pehacain a controlled substance?

According to the regulatory classification of its active ingredients, Lidocaine Hydrochloride is generally not classified as a scheduled substance under the Controlled Substances Act (CSA). Therefore, the product is not associated with the regulatory requirements of a controlled substance.

Q: What information is publicly available about Pehacain's safety classification?

Official documents contain several safety classifications. For instance, the drug is assigned an FDA Pregnancy Category B. Furthermore, the official labeling includes Boxed Warnings that highlight specific, serious risks like methemoglobinemia in susceptible individuals.

Q: Do I need a prescription from a doctor to get Pehacain?

Pehacain is classified as a Human Prescription Drug product. This means that regulatory agencies restrict its use, and it is intended to be administered only by, or under the close supervision of, an experienced medical professional.

Q: Does Pehacain have any risk of dependence or addiction?

The active ingredients in the product are not associated with the risks of abuse or dependence in official regulatory documents. Furthermore, the product is not classified as a scheduled controlled substance by regulatory bodies.

How should Pehacain be stored and disposed of?

How to Store and Dispose of Pehacain (Lidocaine and Adrenaline Injection)

Official regulatory guidelines define specific conditions for storing this injectable solution to maintain its stability and integrity.

Storage Requirements

Pehacain must be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must not be frozen and should be kept in its original container to protect it. Before use, the solution must be visually inspected; if it appears discolored, turbid, or contains particulate matter, it must not be administered. The medication must be stored out of reach of children.

Handling and Disposal

For preservative-free, single-dose vials, any unused solution must be discarded immediately after the initial use. Disposal of the expired or unused medication and its container must comply with all applicable special handling and disposal procedures for pharmaceutical waste.

Pehacain